Should Renal Inflammation Be Targeted While Treating Hypertension?
Should Renal Inflammation Be Targeted While Treating Hypertension?
复制标题
DOI：
10.3389/fphys.2022.886779
复制
发表时间：
2022
影响因子：
4
通讯作者：
中科院分区：
文献类型：
--
作者：
尽管进行了广泛的研究和大量的治疗选择，高血压仍然是全球的负担。了解已知和尚未探索的细胞和分子途径在高血压发生和维持中的病理作用对于推进该领域至关重要。免疫系统过度激活和肾脏炎症被认为是高血压和难治性高血压的替代机制。考虑慢性炎症性疾病（例如自身免疫性疾病）中高血压的病理生理学，其中患者患有自身免疫介导的肾脏炎症以及高血压，可能会揭示可能的因素和新的治疗靶点。在这篇综述中，我们 1) 总结了当前用于控制血压的疗法及其对炎症的已知影响； 2) 提供针对肾脏炎症的必要性的证据，特别是当一线治疗和联合治疗失败时； 3) 讨论用于治疗高血压/肾脏疾病的自身免疫性疾病的疗效。我们的目标是阐明针对某些对当前疗法耐药的患者亚群的肾脏炎症的潜力。
Despite extensive research and a plethora of therapeutic options, hypertension continues to be a global burden. Understanding of the pathological roles of known and underexplored cellular and molecular pathways in the development and maintenance of hypertension is critical to advance the field. Immune system overactivation and inflammation in the kidneys are proposed alternative mechanisms of hypertension, and resistant hypertension. Consideration of the pathophysiology of hypertension in chronic inflammatory conditions such as autoimmune diseases, in which patients present with autoimmune-mediated kidney inflammation as well as hypertension, may reveal possible contributors and novel therapeutic targets. In this review, we 1) summarize current therapies used to control blood pressure and their known effects on inflammation; 2) provide evidence on the need to target renal inflammation, specifically, and especially when first-line and combinatory treatment efforts fail; and 3) discuss the efficacy of therapies used to treat autoimmune diseases with a hypertension/renal component. We aim to elucidate the potential of targeting renal inflammation in certain subsets of patients resistant to current therapies.
登录
查看更多内容
影响因子：
39.2
作者：
Carey, Robert M.;Whelton, Paul K.
通讯作者：
Whelton, Paul K.
DOI：
10.1161/hyp.0000000000000084
发表时间：
2018-11
期刊：
Hypertension (Dallas, Tex. : 1979)
影响因子：
--
作者：
Carey RM;Calhoun DA;Bakris GL;Brook RD;Daugherty SL;Dennison-Himmelfarb CR;Egan BM;Flack JM;Gidding SS;Judd E;Lackland DT;Laffer CL;Newton-Cheh C;Smith SM;Taler SJ;Textor SC;Turan TN;White WB;American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council
通讯作者：
American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council
影响因子：
2.7
作者：
Borovikova, LV;Ivanova, S;Tracey, KJ
通讯作者：
Tracey, KJ
影响因子：
3.9
作者：
Artim-Esen, Bahar;Cene, Erhan;Inanc, Murat
通讯作者：
Inanc, Murat
影响因子：
8.3
作者：
Chan, Christopher T.;Sobey, Christopher G.;Drummond, Grant R.
通讯作者：
Drummond, Grant R.